News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ocular Therapeutix, Inc. Announces Phase 2 Study Results for Sustained Release Dexamethasone



10/1/2013 10:54:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. announces today the results of its Phase 2 sustained release dexamethasone (OTX-DP) study for the treatment of post-operative inflammation and pain. Ocular Therapeutix’s sustained release dexamethasone is administered as a one-time absorbable intracanalicular plug, designed with a four-week tapered release.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Cataract

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES